Jubilant Organosys, the largest CRAMs player, performed well during the first quarter ended June 2006 on account of investment in R&D and export earnings. The company's consolidated net profit went up sharply by 116.4 per cent to Rs 46.10 crore from Rs 21.30 crore in the corresponding period of last year. The standalone net profit also doubled to Rs 47.40 crore as against Rs 23.60 crore. The pharmaceutical and Life Science Products business, the key growth driver, recorded a growth of 43.2 per cent due to significant growth in CRAMS, APIs and Drug Discovery and Development Services business.

Commenting on financial results, Shyam Bhartia, chairman & managing director, said, "We are pleased to report a significant growth in revenue and profits for the quarter. The results confirm that our strategic initiatives are yielding results especially in the focus growth segment of pharmaceutical and life science products. We are the preferred partner to global life science companies due to our unique capability to offer products and services across the value chain. We have plans to further expand this business through out we-evaluated organic and inorganic growth strategy."

The EBDIT touched to Rs 78.9 crore from Rs 42.5 crore and EBDIT margins worked out to 17.5 per cent. The pharma business recorded an increase of 78.4 per cent in PBIT to Rs 39.6 crore as compared to Rs 22.2 crore in Q1 of 2006.

Jubilant's long-term strategy includes a strong focus on the international markets, especially the regulated markets of North America, Europe and Japan, and a thrust on both organic and inorganic initiatives.